Dateline: June 15 2028

Four years ago, 800-million people globally were classed as obese, including 40% of the US population, and Novo Nordisk was the most valuable company in Europe. With Novo’s introduction of an affordable, tablet-form GLP-1 in early 2025, effortless weight loss was no longer the exclusive remit of celebs, tech billionaires and influencers...

This article is free to read if you sign up or sign in.

If you have already registered or subscribed, please sign in to continue.

Questions or problems? Email or call 0860 52 52 00.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.